Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Zhang, Dingyu ^a   Zhang, Xiaolin ^a   Liu, Dan ^a   Liu, Tengfei ^a   Cai, Wenzhi ^a   Yan, Chenghui ^a   Han, Yaling ^a  

^a Shenyang Northern Hospital   (China)

Author keywords

Clopidogrel; Coronary artery disease; High platelet reactivity; Insulin receptor substrate 1; Single nucleotide polymorphism; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE PHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; DUAL SPECIFICITY PHOSPHATASE 2; GENOMIC DNA; INSULIN RECEPTOR SUBSTRATE 1; PADGEM PROTEIN; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; SELP PROTEIN, HUMAN; TICLOPIDINE;

ADULT; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIATION; GENOTYPE; HUMAN; INSULIN RECEPTOR SUBSTRATE 1 GENE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET REACTIVITY; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; SEQUENCE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; HAPLOTYPE; METABOLISM; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; HAPLOTYPES; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MIDDLE AGED; P-SELECTIN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85007426140     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0362-0     Document Type: Article

References (40)

1. Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovascular Imaging. 2012;5(5):540-9. doi:10.1016/j.jcmg.2011.12.019.
2. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657-66. doi:10.1016/j.jacc.2006.10.050.
3. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822-34. doi:10.1016/j.jacc.2007.07.051.
4. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-22. doi:10.1161/01.ATV.0000199519.37089.a0.
5. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120-6.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434-44.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430-5.
8. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48(2):298-304. doi:10.1016/j.jacc.2006.03.038.
9. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32(4):531-40. doi:10.2337/dc08-2064.
10. Vivas D, Garcia-Rubira JC, Bernardo E, Angiolillo DJ, Martin P, Calle A, et al. Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia. Rev Esp Cardiol. 2013;. doi:10.1016/j.recesp.2013.05.021.
11. Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54(12):1041-57. doi:10.1016/j.jacc.2009.04.084.
12. Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes. 2010;59(6):1487-95. doi:10.2337/db09-1008.
13. Feng X, Tucker KL, Parnell LD, Shen J, Lee YC, Ordovas JM, et al. Insulin receptor substrate 1 (IRS1) variants confer risk of diabetes in the boston puerto rican health study. Asia Pac J Clin Nutr. 2013;22(1):150-9. doi:10.6133/apjcn.2013.22.1.09.
14. Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2011;58(1):30-9. doi:10.1016/j.jacc.2011.02.040.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. doi:10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S.
16. Davidovich O, Kimmel G, Shamir R. GEVALT: an integrated software tool for genotype analysis. BMC Bioinformatics. 2007;8:36. doi:10.1186/1471-2105-8-36.
17. Halperin E, Kimmel G, Shamir R. Tag SNP selection in genotype data for maximizing SNP prediction accuracy. Bioinformatics. 2005;21(Suppl 1):i195-203. doi:10.1093/bioinformatics/bti1021.
18. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation. 2007;115(6):708-16. doi:10.1161/CIRCULATIONAHA.106.667741.
19. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29(18):2202-11. doi:10.1093/eurheartj/ehn287.
20. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3 trial. Eur Heart J. 2011;32(7):838-46. doi:10.1093/eurheartj/ehq494.
21. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541-7. doi:10.1016/j.jacc.2007.05.049.
22. Sethi SS, Akl EG, Farkouh ME. Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. Curr DiabRep. 2012;12(3):294-304. doi:10.1007/s11892-012-0272-9.
23. Andersson C, Lyngbaek S, Nguyen CD, Nielsen M, Gislason GH, Kober L, et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA. 2012;308(9):882-9. doi:10.1001/2012.jama.10779.
24. Sakata K, Waseda K, Kume T, Otake H, Nakatani D, Yock PG, et al. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses. Circ Cardiovasc Interv. 2012;5(6):763-71. doi:10.1161/CIRCINTERVENTIONS.111.962878.
25. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004;279(5):3254-64. doi:10.1074/jbc. M305474200.
26. Liu ME, Liao YC, Lin RT, Wang YS, Hsi E, Lin HF, et al. A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis. Atherosclerosis. 2013;228(1):161-7. doi:10.1016/j.atherosclerosis.2013.01.036.
27. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7(16):2485-92.
28. MicroRNA.org-targets and expression. http://www.microrna.org/microrna/home.do. Accessed 6 Jan 2015.
29. Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol. 2011;57(2):194-201. doi:10.1016/j.jjcc.2010.10.007.
30. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. doi:10.1056/NEJMoa0808227.
31. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-17 doi:10.1016/S0140-6736(08)61845-0.
32. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-34. doi:10.1016/j.jacc.2007.12.056.
33. Mizobe M, Hokimoto S, Akasaka T, Arima Y, Kaikita K, Morita K, et al. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. Thromb Res. 2014;134(1):72-7. doi:10.1016/j.thromres.2014.04.020.
34. Gajos G, Konieczynska M, Zalewski J, Undas A. Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc Diabetol. 2015;14:44. doi:10.1186/s12933-015-0207-2.
35. Schuette C, Steffens D, Witkowski M, Stellbaum C, Bobbert P, Schultheiss HP, et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc Diabetol. 2015;14:15. doi:10.1186/s12933-015-0182-7.
36. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482.
37. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327.
38. Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE, et al. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. Int J Cardiol. 2015;194:60-2. doi:10.1016/j.ijcard.2015.05.085.
39. Alexopoulos D, Vogiatzi C, Stavrou K, Vlassopoulou N, Perperis A, Pentara I, et al. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. Cardiovasc Diabetol. 2015;14:68. doi:10.1186/s12933-015-0232-1.
40. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505-16. doi:10.1016/j.jacc.2006.11.044.